Skip to content
Participate in our active studies
Subscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
Home
Company
Corporate Overview
Executive Commitee
Scientific Committee
Values
Science
Overview
Masitinib in neurodegenerative disorders
Masitinib in inflammatory diseases
AB8939 in oncology
Publications
Pipeline
Pipeline Overview
Masitinib
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Indolent Systemic Mastocytosis
Mast Cell Activation Syndrome
AB8939
News and Media
Press releases
In the Media
Webcasts
Investors
Why invest in AB Science
Investor Kit
Regulated information
Annual reports
Half-year reports
Social and environmental responsabilities
Shareholders General Meeting
Outstanding shares and voting rights
Regulated agreements
Board of Directors Charter
Information document
Stock Information
General Information
Analyst Coverage
Financial Calendar
Events
Masivet®
About Masivet®
Medical information and Pharmacovigilance
Careers
Contact
Search:
Home
Company
Corporate Overview
Executive Commitee
Scientific Committee
Values
Science
Overview
Masitinib in neurodegenerative disorders
Masitinib in inflammatory diseases
AB8939 in oncology
Publications
Pipeline
Pipeline Overview
Masitinib
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Indolent Systemic Mastocytosis
Mast Cell Activation Syndrome
AB8939
News and Media
Press releases
In the Media
Webcasts
Investors
Why invest in AB Science
Investor Kit
Regulated information
Annual reports
Half-year reports
Social and environmental responsabilities
Shareholders General Meeting
Outstanding shares and voting rights
Regulated agreements
Board of Directors Charter
Information document
Stock Information
General Information
Analyst Coverage
Financial Calendar
Events
Masivet®
About Masivet®
Medical information and Pharmacovigilance
Careers
Contact
Information document
You are here:
Home
Investors
Regulated information
Information document
INFORMATION DOCUMENT
Download PDF
Go to Top
